Steven J Skates
Overview
Explore the profile of Steven J Skates including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
4951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhuang L, Park S, Skates S, Prosper A, Aberle D, Hsu W
ArXiv
. 2025 Feb;
PMID: 39990791
Cancer evolves continuously over time through a complex interplay of genetic, epigenetic, microenvironmental, and phenotypic changes. This dynamic behavior drives uncontrolled cell growth, metastasis, immune evasion, and therapy resistance, posing...
2.
Bedia J, Jacobs I, Ryan A, Gentry-Maharaj A, Burnell M, Singh N, et al.
EBioMedicine
. 2025 Jan;
112:105554.
PMID: 39808947
Background: The ovarian cancer (OC) preclinical detectable phase (PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from...
3.
Haber D, Skates S
Cancer Discov
. 2024 Nov;
14(11):2025-2027.
PMID: 39485252
Annual low-dose CT screening of individuals with a smoking history identifies early curable lung tumors and reduces cancer mortality by 20%, yet only a minority of eligible patients undergo such...
4.
Simon J, Mikhael P, Graur A, Chang A, Skates S, Osarogiagbon R, et al.
Invest Radiol
. 2024 Oct;
PMID: 39437009
Purpose: Sybil is a validated publicly available deep learning-based algorithm that can accurately predict lung cancer risk from a single low-dose computed tomography (LDCT) scan. We aimed to study the...
5.
Winn-Deen E, Bortolin L, Gusenleitner D, Biette K, Copeland K, Gentry-Maharaj A, et al.
J Mol Diagn
. 2024 Sep;
26(12):1129-1148.
PMID: 39326669
The low incidence of ovarian cancer (OC) dictates that any screening strategy needs to be both highly sensitive and highly specific. This study explored the utility of detecting multiple colocalized...
6.
Al-Alem L, Prendergast J, Clark J, Zarrella B, Zarrella D, Hill S, et al.
J Ovarian Res
. 2024 Apr;
17(1):71.
PMID: 38566237
Background: Ovarian cancer remains the deadliest of the gynecologic cancers in the United States. There have been limited advances in treatment strategies that have seen marked increases in overall survival....
7.
Han C, Bedia J, Yang W, Hawley S, Bergan L, Hopper M, et al.
Br J Cancer
. 2024 Jan;
130(5):861-868.
PMID: 38195887
Background: Multiple antigens, autoantibodies (AAb), and antigen-autoantibody (Ag-AAb) complexes were compared for their ability to complement CA125 for early detection of ovarian cancer. Methods: Twenty six biomarkers were measured in...
8.
Han C, Lu K, Corrigan G, Perez A, Kohring S, Celestino J, et al.
J Clin Oncol
. 2024 Jan;
42(10):1102-1109.
PMID: 38194613
Purpose: The Normal Risk Ovarian Screening Study (NROSS) tested a two-stage screening strategy in postmenopausal women at conventional hereditary risk where significantly rising cancer antigen (CA)-125 prompted transvaginal sonography (TVS)...
9.
Dilley J, Gentry-Maharaj A, Ryan A, Burnell M, Manchanda R, Kalsi J, et al.
Gynecol Oncol
. 2023 Nov;
179:123-130.
PMID: 37980767
Objective: UKCTOCS provides an opportunity to explore symptoms in preclinical invasive epithelial ovarian cancer (iEOC). We report on symptoms in women with pre-clinical (screen-detected) cancers (PC) compared to clinically diagnosed...
10.
Menon U, Gentry-Maharaj A, Burnell M, Apostolidou S, Ryan A, Kalsi J, et al.
Health Technol Assess
. 2023 Oct;
:1-38.
PMID: 37843101
Abstract: Randomised controlled trials are challenging to deliver. There is a constant need to review and refine recruitment and implementation strategies if they are to be completed on time and...